ELEV Stock News & Analysis | Latest Updates

ELEVATION ONCOLOGY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Elevation Oncology, Inc. - ELEV

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Elevation Oncology, Inc. (NasdaqCM: ELEV) to Concentra Biosciences, LLC. Under the terms of the proposed transaction, shareholders of Elevation will receive $0.36 in cash per share, plus one non-tradeable contingent value right representing the right to receive: (i) 100% of the closing net cash in e

June 10, 2025Mergers

ELEV News

ELEVATION ONCOLOGY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick &amp; Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Elevation Oncology, Inc. - ELEV

JMP Securities Reiterates Market Perform on Elevation Oncologyto Market Perform

HC Wainwright & Co. Downgrades Elevation Oncology to Neutral, Lowers Price Target to $0.36

William Blair Downgrades Elevation Oncology to Market Perform

Trading Halt: Halt status updated at 8:25:00 AM ET: Quotation Resumption: News and Resumption Times

Concentra Biosciences To Acquire Elevation Oncology For $0.36 In Cash Per Share Of Elevation Oncology Common Stock, Plus One Non-Tradeable Contingent Value Right

Trading Halt: Halted at 7:55:00 a.m. ET - Trading Halt: Halt News Pending

Elevation Oncology Q1 EPS $(0.24) Misses $(0.19) Estimate

Elevation Oncology To Present Data For EO-1022 At American Association for Cancer Research Annual Meeting 2025

Stephens & Co. Downgrades Elevation Oncology to Equal-Weight, Lowers Price Target to $1

Piper Sandler Downgrades Elevation Oncology to Neutral, Lowers Price Target to $0.7

Citizens Capital Markets Downgrades Elevation Oncology to Market Perform, Maintains Price Target to $7

Leerink Partners Downgrades Elevation Oncology to Market Perform, Lowers Price Target to $1

HC Wainwright & Co. Maintains Buy on Elevation Oncology, Lowers Price Target to $1

Elevation Oncology Stops Gastric Cancer Study, Slashes Staff By 70%

Elevation Oncology To Discontinue Development Of EO-3021; Continuing To Advance Potentially Differentiated HER3 ADC, EO-1022, Which Utilizes An MMAE Payload And Glycan Site-Specific Conjugation

Citizens Capital Markets Reiterates Market Outperform on Elevation Oncology, Maintains $7 Price Target

HC Wainwright & Co. Reiterates Buy on Elevation Oncology, Maintains $6 Price Target

Stephens & Co. Reiterates Overweight on Elevation Oncology, Maintains $5 Price Target

Elevation Oncology Q4 2024 GAAP EPS $(0.18) Beats $(0.22) Estimate

HC Wainwright & Co. Reiterates Buy on Elevation Oncology, Maintains $6 Price Target

Elevation Oncology Advances EO-3021 Trials to Target Advanced Gastric and GEJ Cancers with Improved Care

JMP Securities Reiterates Market Outperform on Elevation Oncology, Maintains $7 Price Target

ELEVATION ONCOLOGY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Elevation Oncology, Inc. - ELEV